What is the recommended management for polycythemia, including primary polycythemia vera and secondary polycythemia?

Management of Polycythemia

All patients with polycythemia vera require therapeutic phlebotomy to maintain hematocrit <45% and low-dose aspirin (81-100 mg daily) unless contraindicated 1, 2. This forms the foundation of treatment regardless of risk stratification.

Initial Diagnostic Approach

First, distinguish between primary (polycythemia vera) and secondary polycythemia:

• Test for JAK2 mutation - present in >95% of polycythemia vera cases 2
• Measure serum erythropoietin levels - suppressed in PV, elevated in secondary causes
• If polycythemia is isolated (no leukocytosis/thrombocytosis), prioritize investigating secondary causes: chronic hypoxia, sleep apnea, smoking, SGLT2 inhibitors, androgens, or erythropoietin-secreting tumors 3

Polycythemia Vera Management

Risk Stratification

Low-risk patients (age <60 years AND no prior thrombosis):

• Phlebotomy to maintain hematocrit <45%
• Aspirin 81-100 mg daily
• Monitor every 3-6 months 1

High-risk patients (age ≥60 years OR prior thrombosis history):

• Phlebotomy + aspirin (as above)
• Add cytoreductive therapy 1, 2

Cytoreductive Therapy Selection

First-line cytoreductive agent:

• Hydroxyurea is the standard first-line cytoreductive therapy for high-risk patients 4, 1
• Recombinant interferon alfa (ropeginterferon alfa-2b or pegylated interferon alfa-2a) is preferred for younger patients requiring long-term treatment 4, 5

Second-line options (for hydroxyurea resistance/intolerance):

• Ruxolitinib receives a strong recommendation despite moderate evidence quality 4
• Interferon alfa (if not previously used) 4, 5
• Choice between these should be based on patient age: interferon for younger patients, ruxolitinib for older patients or those with significant symptom burden 4

Indications for Cytoreductive Therapy in Low-Risk Patients

Even low-risk patients should start cytoreductive therapy if they develop 5:

• Strictly defined phlebotomy intolerance
• Symptomatic progressive splenomegaly
• Persistent leukocytosis (>15 × 10⁹/L)
• Progressive leukocytosis (≥100% increase if baseline <10 × 10⁹/L or ≥50% increase if baseline >10 × 10⁹/L)
• Extreme thrombocytosis (>1500 × 10⁹/L)
• Inadequate hematocrit control requiring frequent phlebotomies
• Persistently high cardiovascular risk
• Persistently high symptom burden

Special Considerations

Pregnancy: Use interferon alfa as the cytoreductive agent of choice if needed 6

Extreme thrombocytosis (≥1000 × 10⁹/L): Avoid aspirin due to acquired von Willebrand disease risk and increased bleeding 2

Very elderly patients: Consider intermittent busulphan 4

Secondary Polycythemia Management

There is no robust evidence base for routine venesection in secondary polycythemia 7. Management should focus on treating the underlying cause:

• Address hypoxia: Optimize treatment of sleep apnea, COPD, or other pulmonary conditions
• Eliminate causative agents: Discontinue androgens, SGLT2 inhibitors if possible
• Smoking cessation: Critical intervention as smoking shows strong association with polycythemia 8

Consider venesection only in specific circumstances:

• Hematocrit >0.56 in patients with hypoxic lung disease 7
• Target hematocrit <0.55 for idiopathic polycythemia 7
• Presence of polycythemia-related symptoms
• History of arterial or unprovoked venous thrombosis 7

Critical Pitfalls to Avoid

• Do not use hematocrit <45% target universally - may need individualization to 42% for women or based on progressive symptoms 1
• Perform bone marrow biopsy before initiating cytoreductive therapy to rule out progression to myelofibrosis 1
• Do not assume all polycythemia is PV - secondary causes are far more common in general practice 3, 7
• Monitor for disease progression: 12.7% develop myelofibrosis and 6.8% develop acute myeloid leukemia 2